Press Release

 Back to News       Contact Us     Home

Seattle, Washington, (BUSINESS WIRE) -- May 23, 2006 – Accium BioSciences, Inc., (Accium) the first fully-commercial Accelerator Mass Spectrometry (AMS) analytical facility in the US, and Quintiles Transnational Corp., the world’s leading pharmaceutical services company, today announced the establishment of a partnership to offer turnkey Exploratory-IND, Microdosing and Information-Rich™ Phase I clinical trials services to biopharmaceutical  researchers.   Accium’s Accelerator Mass Spectrometer-based study design expertise and core bioanalytical capabilities combined with the clinical development and regulatory experience and expertise of Quintiles delivers a seamless solution to the critical decision process in early drug development.

“This partnership leverages Accium’s unique bioanalytical capabilities with the Quintiles’ best practice clinical development processes to generate critical information very early in clinical development.  By working together, we can now provide biopharmaceutical sponsors with a one-stop-shop solution for critical early phase drug trials,” stated Michael Chansler, Vice President of Business Development for Accium.  “Quintiles is recognized as the leader in pharmaceutical contract research.  Establishing this partnership and successfully completing the stringent Quintiles quality audit ensures that our clients receive consistent, professional and timely clinical and bioanalytical services, whether they contract through Accium or Quintiles.”

Joseph Lacz, Ph.D., Vice President, Clinical Technology Services, Quintiles, said: “The FDA has issued the Exploratory IND guidance that gives the pharmaceutical industry new tools to conduct pharmacokinetics (PK) and ADME (absorption, distribution, metabolism and excretion) trials earlier in the clinical development process. Quintiles is pleased to partner with Accium BioSciences to provide AMS-based bioanalytical capabilities supporting client requests for microdosing trials. Using these state-of-the-art trial designs and tools, pharmaceutical companies have the ability to select the best compound for further development earlier in the process. This allows an efficient use of their R&D budgets and a more rapid advancement of their new therapies.”

Seattle based Accium BioSciences, (http://www.acciumbio.com) is the first company to fully commercialize Accelerator Mass Spectrometry (AMS) services in the U.S. with a focus on early drug development.  Accium offers a full range of services for preclinical ADME testing, Exploratory IND / microdosing studies and Information-Rich^™ Phase 1 clinical trials.  Combining a state-of-the art AMS analytical facility with a network of qualified and trusted partners, Accium offers a one-stop solution to enable earlier go / no-go decisions in the drug development process.

Quintiles Transnational is the global leader in pharmaceutical services, improving healthcare worldwide by providing innovative, quality professional expertise, market intelligence and partnering solutions to meet the dynamic needs of the pharmaceutical, biotechnology and healthcare industries.  Quintiles has 16,000 specialized employees and offices in 50 countries.  For more information visit the company's Web site at www.quintiles.com.

For additional information, visit www.acciumbio.com or contact Michael Chansler at   (206) 281-3915.